| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7803839 | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
Nov, 2029
(5 years from now) | |
| US10478400 | GENENTECH INC | Immediate-release tablets containing combimetinib and methods of making and using the same |
Jun, 2036
(12 years from now) | |
| US10590102 | GENENTECH INC | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone |
Jun, 2036
(12 years from now) | |
| US11254649 | GENENTECH INC | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone |
Jun, 2036
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8362002 | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
Oct, 2026
(2 years from now) | |
| US11597699 | GENENTECH INC | MEK inhibitors and methods of their use |
Oct, 2026
(2 years from now) | |
|
US8362002 (Pediatric) | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
Apr, 2027
(2 years from now) | |
|
US7803839 (Pediatric) | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
May, 2030
(6 years from now) | |
| US11087354 | GENENTECH INC | Combination therapies |
Jun, 2034
(10 years from now) | |
|
US11087354 (Pediatric) | GENENTECH INC | Combination therapies |
Dec, 2034
(10 years from now) | |
|
US10478400 (Pediatric) | GENENTECH INC | Immediate-release tablets containing combimetinib and methods of making and using the same |
Dec, 2036
(12 years from now) | |
|
US11254649 (Pediatric) | GENENTECH INC | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone |
Dec, 2036
(12 years from now) | |
|
US10590102 (Pediatric) | GENENTECH INC | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone |
Dec, 2036
(12 years from now) | |
Cotellic is owned by Genentech Inc.
Cotellic contains Cobimetinib Fumarate.
Cotellic has a total of 13 drug patents out of which 0 drug patents have expired.
Cotellic was authorised for market use on 10 November, 2015.
Cotellic is available in tablet;oral dosage forms.
Cotellic can be used as as a single agent for the treatment of adult patients with histiocytic neoplasms, method of using cobimetinib for the treatment of melanoma.
Drug patent challenges can be filed against Cotellic from 28 January, 2025.
The generics of Cotellic are possible to be released after 30 December, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-902) | Oct 28, 2025 |
| M(M-278) | Jul 28, 2025 |
| Orphan Drug Exclusivity(ODE-416) | Oct 28, 2029 |
| Pediatric Exclusivity(PED) | Jan 28, 2026 |
| Orphan Drug Exclusivity(ODE-101) | Nov 10, 2022 |
| New Chemical Entity Exclusivity(NCE) | Nov 10, 2020 |
| Orphan Drug Exclusivity(ODE) | Nov 10, 2022 |
Drugs and Companies using COBIMETINIB FUMARATE ingredient
NCE-1 date: 28 January, 2025
Market Authorisation Date: 10 November, 2015
Treatment: Method of using cobimetinib for the treatment of melanoma; As a single agent for the treatment of adult patients with histiocytic neoplasms
Dosage: TABLET;ORAL
COTELLIC family patents
